IBEX

# TRUSTED CANCER DIAGNOSTICS FOR ALL

# THE GALEN™ PLATFORM

## Trusted AI

## First Read

**Integrated Diagnostics:**
**enhanced workflow during case review**

- Improve diagnostic accuracy
- Increase pathologists' productivity and improve lab workflow with AI-powered insights
- Reduce turnaround time
- AI-driven case prioritization, pre-order staining, grading, tumor sizing and more
- Streamline reporting
- Ready for integration with scanning platforms, pathology workflow and lab information software
- Field proven. Deployed worldwide and used in everyday practice

## Second Read

**Real Time Quality Control:**
**safety net for 100% of reported cases**

- Alerts on misdiagnosed and mis-graded cases
- Increase confidence levels and reduce error
- Clinical-grade accuracy
- Field proven. Deployed worldwide and used in everyday practice
- No impact on routine workflows
- Easy to deploy

The Galen Breast, Galen Gastric and Galen Prostate solutions are CE marked. The solutions are not cleared by the FDA and for Research Use Only (RUO) in the United States. For more information, including indication for use and regulatory approval in other countries, contact Ibex Medical Analytics

Galen™ Prostate

Galen™ Breast

Galen™ Gastric

Cancer heatmap



Gleason heatmap

Reporting tool



Point of interest for quick review



# AI-POWERED PATHOLOGY

## Clinical Excellence

### Breast

Invasive cancer detection (including rare subtypes):

AUC - 0.990

Sensitivity – 95.5%

Specificity – 93.6%

DCIS detection:

AUC - 0.980

Sensitivity – 93.2%

Specificity – 93.8%

Broad range of detection capabilities:

IDC vs. ILC, DCIS grading, TILs, LVIs, hyperplasia, inflammation and more

Presented at ECP 2021

### Prostate

Cancer vs. benign*:

AUC - 0.991

Sensitivity – 98.4%

Specificity – 97.3%

Pathologists using AI vs. microscope in primary diagnosis**:

27% reduction in diagnosis time

32% reduction in major discrepancy rate

37% productivity gain

12-24 hours reduction in lab turnaround time

Going beyond cancer detection*:

G3-4 vs. G5+: AUC - 0.971

G6 vs. G7+: AUC - 0.941

Perineural invasion: AUC - 0.957

*Pantanowitz et al., The Lancet Digital Health, Aug. 2020

**Presented at USCAP 2021 and ECP 2021

### Gastric

Cancer vs. benign:

AUC - 0.994

Sensitivity – 96.7%

Specificity – 97.3%

H. pylori detection:

AUC - 0.966

Sensitivity – 91.4%

Specificity – 91.7%

The only AI solution for the GI tract

Galen Gastric goes beyond cancer detection and enables detection of lymphomas, neuroendocrine neoplasms, intestinal metaplasia, adenoma, LG dysplasia and more

Galen Gastric can drive a more cost-effective workflow by detecting H.pylori and reducing turnaround time and stain ordering

Presented at USCAP 2022

Rigorously blinded, multi-site clinical studies. Galen was tested against multiple independent pathologists and on various staining platforms and scanning systems

IBEX

Ibex Medical Analytics pioneers AI-powered cancer diagnostics in pathology. We empower physicians to provide every patient with an accurate, timely and personalized cancer diagnosis with clinical-grade AI algorithms and digital workflows that help detect and grade cancer. Our Galen™ platform is deployed worldwide, supporting pathologists, health systems and diagnostic providers in improving the quality and accuracy of diagnosis, implementing comprehensive quality control, reducing turnaround times and boosting productivity with more efficient workflows.

Ibex Medical Analytics
101 Rokach Blvd., Tel Aviv 6153101, Israel
202 Washington St., Brookline, MA 02445
info@ibex-ai.com
**www.ibex-ai.com**

MKT-0009-00 Rev. 05